JP2021522162A5 - - Google Patents
Info
- Publication number
- JP2021522162A5 JP2021522162A5 JP2020556851A JP2020556851A JP2021522162A5 JP 2021522162 A5 JP2021522162 A5 JP 2021522162A5 JP 2020556851 A JP2020556851 A JP 2020556851A JP 2020556851 A JP2020556851 A JP 2020556851A JP 2021522162 A5 JP2021522162 A5 JP 2021522162A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- ror
- binding molecule
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172867A JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
| JP2025117193A JP2025137618A (ja) | 2018-04-18 | 2025-07-11 | 抗ｒｏｒ抗体構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659635P | 2018-04-18 | 2018-04-18 | |
| US62/659,635 | 2018-04-18 | ||
| PCT/US2019/028051 WO2019204564A1 (en) | 2018-04-18 | 2019-04-18 | Anti-ror antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172867A Division JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522162A JP2021522162A (ja) | 2021-08-30 |
| JP2021522162A5 true JP2021522162A5 (enExample) | 2022-04-25 |
Family
ID=68239890
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556851A Pending JP2021522162A (ja) | 2018-04-18 | 2019-04-18 | 抗ｒｏｒ抗体構築物 |
| JP2023172867A Withdrawn JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
| JP2025117193A Pending JP2025137618A (ja) | 2018-04-18 | 2025-07-11 | 抗ｒｏｒ抗体構築物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172867A Withdrawn JP2023168551A (ja) | 2018-04-18 | 2023-10-04 | 抗ｒｏｒ抗体構築物 |
| JP2025117193A Pending JP2025137618A (ja) | 2018-04-18 | 2025-07-11 | 抗ｒｏｒ抗体構築物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12084496B2 (enExample) |
| EP (1) | EP3797122A4 (enExample) |
| JP (3) | JP2021522162A (enExample) |
| KR (1) | KR20200143470A (enExample) |
| CN (1) | CN112384533A (enExample) |
| AU (2) | AU2019256431B2 (enExample) |
| BR (1) | BR112020021269A2 (enExample) |
| CA (1) | CA3097704A1 (enExample) |
| EA (1) | EA202092202A1 (enExample) |
| IL (2) | IL316574A (enExample) |
| MX (4) | MX2020010881A (enExample) |
| MY (1) | MY207121A (enExample) |
| PH (1) | PH12020551716A1 (enExample) |
| SG (1) | SG11202010235QA (enExample) |
| WO (1) | WO2019204564A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326918A (en) * | 2016-10-19 | 2026-05-01 | Invenra Inc | Antibody structures |
| CN113480656B (zh) * | 2020-08-24 | 2022-06-03 | 岸迈生物科技(苏州)有限公司 | 抗ror1抗体 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| WO2023019121A2 (en) * | 2021-08-09 | 2023-02-16 | Merck Patent Gmbh | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| TW202346330A (zh) * | 2022-03-18 | 2023-12-01 | 美商長典生物晶片股份有限公司 | 抗豬繁殖與呼吸道綜合症病毒的抗體及其用途 |
| TW202408589A (zh) | 2022-06-30 | 2024-03-01 | 美商舒卓生物製藥公司 | 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法 |
| WO2024207177A1 (en) * | 2023-04-04 | 2024-10-10 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| AU2023313641A1 (en) * | 2022-07-26 | 2025-03-13 | Aimed Bio Inc. | Anti-ror1 antibody and use thereof |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| GB202216284D0 (en) * | 2022-11-02 | 2022-12-14 | Ucl Business Ltd | Self-regulation |
| EP4638506A1 (en) * | 2022-12-20 | 2025-10-29 | Oncternal Therapeutics, Inc. | Combination therapies for the treatment of cancer |
| KR20260056331A (ko) * | 2023-07-20 | 2026-04-24 | 엑셀리시스, 인코포레이티드 | 활성화 가능한 티로신-단백질 키나제 막 수용체(ror) 항체-약물 접합체 및 이의 용도 |
| CN121752598A (zh) * | 2023-07-20 | 2026-03-27 | 埃克塞里艾克西斯公司 | 酪氨酸蛋白激酶膜受体1 (ror1)抗体-药物缀合物和其用途 |
| CN121843961A (zh) * | 2023-07-20 | 2026-04-10 | 埃克塞里艾克西斯公司 | 可活化的ror结合剂和其用途 |
| WO2025132812A1 (en) * | 2023-12-20 | 2025-06-26 | Antalgenics, S.L. | Phospholipase c inhibitor peptides and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| AU2010238723A1 (en) * | 2009-04-23 | 2011-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| WO2011079902A2 (en) * | 2009-12-18 | 2011-07-07 | Biolnvent International Ab | Biological materials and uses thereof |
| WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| EP3219731A1 (en) | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| CA2881966C (en) * | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| AU2015329966A1 (en) * | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer |
| CA2963692A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
| JP6904902B2 (ja) | 2014-12-05 | 2021-07-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ドメイン交換抗体 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| AR103442A1 (es) | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| WO2016187220A2 (en) | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| CN109311982A (zh) * | 2016-01-20 | 2019-02-05 | 斯克利普斯研究所 | Ror2抗体组合物和相关方法 |
| JP2019506158A (ja) | 2016-01-22 | 2019-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| IL326918A (en) | 2016-10-19 | 2026-05-01 | Invenra Inc | Antibody structures |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
-
2019
- 2019-04-18 MX MX2020010881A patent/MX2020010881A/es unknown
- 2019-04-18 SG SG11202010235QA patent/SG11202010235QA/en unknown
- 2019-04-18 EP EP19789299.5A patent/EP3797122A4/en active Pending
- 2019-04-18 CN CN201980040982.8A patent/CN112384533A/zh active Pending
- 2019-04-18 CA CA3097704A patent/CA3097704A1/en active Pending
- 2019-04-18 KR KR1020207032901A patent/KR20200143470A/ko active Pending
- 2019-04-18 US US17/048,549 patent/US12084496B2/en active Active
- 2019-04-18 AU AU2019256431A patent/AU2019256431B2/en active Active
- 2019-04-18 EA EA202092202A patent/EA202092202A1/ru unknown
- 2019-04-18 JP JP2020556851A patent/JP2021522162A/ja active Pending
- 2019-04-18 MY MYPI2020005435A patent/MY207121A/en unknown
- 2019-04-18 BR BR112020021269-5A patent/BR112020021269A2/pt unknown
- 2019-04-18 IL IL316574A patent/IL316574A/en unknown
- 2019-04-18 WO PCT/US2019/028051 patent/WO2019204564A1/en not_active Ceased
-
2020
- 2020-10-14 MX MX2025001900A patent/MX2025001900A/es unknown
- 2020-10-14 MX MX2025001906A patent/MX2025001906A/es unknown
- 2020-10-14 IL IL278061A patent/IL278061A/en unknown
- 2020-10-14 MX MX2025001902A patent/MX2025001902A/es unknown
- 2020-10-16 PH PH12020551716A patent/PH12020551716A1/en unknown
-
2023
- 2023-10-04 JP JP2023172867A patent/JP2023168551A/ja not_active Withdrawn
-
2024
- 2024-08-12 US US18/801,013 patent/US20240392002A1/en active Pending
-
2025
- 2025-07-11 JP JP2025117193A patent/JP2025137618A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202585A patent/AU2026202585A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| JP2021534096A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2023123726A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2021508469A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2023504016A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2018522541A5 (enExample) | ||
| JP2021521781A5 (enExample) | ||
| JP2019534277A5 (enExample) | ||
| JP2018532766A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2024520666A5 (enExample) | ||
| CN106831996B (zh) | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| IL295996A (en) | Miniature guidance and navigation control (minignc) of antibody-like proteins and methods of production and use thereof | |
| JP2020515277A5 (enExample) | ||
| JP2022545741A5 (enExample) | ||
| JP2024508808A5 (enExample) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JP2023506834A5 (enExample) |